Longeveron (LGVN) Net Income towards Common Stockholders (2020 - 2026)
Longeveron (LGVN) posted quarterly Net Income towards Common Stockholders of -$5.5 million for Q1 2026, up 14.64% year-over-year from -$4.8 million in Q1 2025, and down 1.86% quarter-over-quarter from -$5.4 million in Q4 2025.
Longeveron (LGVN) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Longeveron's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$5.5 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 14.64% year-over-year to -$5.5 million; the TTM figure through Mar 2026 stood at -$23.2 million (up 14.12% YoY), while the FY2025 annual figure was -$22.7 million, up 7.79% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$5.5 million, down from -$5.4 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$4.1 million in Q4 2024, with the low at -$42.7 million in Q1 2023.
- The 5-year median for Net Income towards Common Stockholders is -$5.4 million (2025), against an average of -$7.9 million.
- The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders tumbled 942.87% in 2023, then soared 89.9% in 2024.
- Longeveron's Net Income towards Common Stockholders stood at -$4.5 million in 2022, then slumped by 35.25% to -$6.0 million in 2023, then jumped by 32.3% to -$4.1 million in 2024, then tumbled by 33.4% to -$5.4 million in 2025, then retreated by 1.86% to -$5.5 million in 2026.
- Business Quant data shows LGVN's Net Income towards Common Stockholders at -$5.5 million in Q1 2026, -$5.4 million in Q4 2025, and -$7.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | -6.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.50 Mn |
| Mar 31, 2026 | -5.55 Mn |
| Dec 31, 2025 | -5.44 Mn |
| Sep 30, 2025 | -7.22 Mn |
| Jun 30, 2025 | -5.03 Mn |
| Mar 31, 2025 | -6.50 Mn |
| Dec 31, 2024 | -4.08 Mn |
| Sep 30, 2024 | -4.57 Mn |
| Jun 30, 2024 | -11.91 Mn |
| Mar 31, 2024 | -4.31 Mn |
| Dec 31, 2023 | -6.03 Mn |
| Sep 30, 2023 | -5.90 Mn |
| Jun 30, 2023 | -5.63 Mn |
| Mar 31, 2023 | -42.72 Mn |
| Dec 31, 2022 | -4.46 Mn |
| Sep 30, 2022 | -5.24 Mn |
| Jun 30, 2022 | -4.92 Mn |
| Mar 31, 2022 | -4.10 Mn |
| Dec 31, 2021 | 44.90 Mn |
| Sep 30, 2021 | -22.91 Mn |